Business Wire

Celltrion Launches Bio CDMO Business for the Development of New Drugs

Jaa

Celltrion (KRX:068270) made an announcement that it will launch Bio CDMO (Contract Development and Manufacturing) business, in a bid to pursue open innovation for development of new drugs, at the 2018 BIO International Convention, the world’s premier life sciences event being held in Boston, June 4-7.

‘Bio CDMO’ refers to i) outsourcing of biologic cell line development and production process, etc., and ii) manufacture outsourcing of non-clinical material, clinical material, and commercialized material.

Unlike regular Bio CDMO businesses, Celltrion’s CDMO business aims to collaborate and partner with research institutes and biotech firms, possessing a new drug candidate molecules, in order to successfully commercialize the aforementioned new drug candidate molecules.

Celltrion plans to support partnered firms by sharing Celltrion’s accumulated biologics development expertise, and may, through consultation and discussion, provide development cost or license in the molecule(s).

Celltrion is initially focusing on specific therapeutic areas which have the greatest synergy with Celltrion’s portfolio - such as autoimmune diseases (rheumatoid arthritis, inflammatory bowel diseases, etc.), breast cancer, lymphoma, and cardiovascular diseases - and is planning to gradually expand its therapeutic areas of interest.

Celltrion spokesperson stated that “At 2018 BIO USA, Celltrion is not only promoting the new CDMO business, but is also meeting with potential partnership candidates. Through various “open innovation strategy”, including this new CDMO business, Celltrion will expand its new drug pipeline portfolio and take a closer step in becoming a global biopharmaceutical corporation.”

About Celltrion, Inc.

Headquartered in Incheon, Korea, Celltrion is a leading biopharmaceutical company, specializing in research, development and manufacture of biosimilar and innovative drugs. Celltrion strives to provide more affordable biosimilar mAbs to patients who previously had limited access to advanced therapeutics. Celltrion received FDA and EC’s approval for INFLECTRA® and Remsima®, respectively, which is the world’s first mAb biosimilar to receive approval from a regulatory agency in a developed country. For more information, visit www.celltrion.com.

About 2018 BIO International Convention

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO), which represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO International Convention is in Boston, June 4-7. Attendees can access the global biotech and pharma community via Partnering, attend 500 education sessions and network with 16,000+ attendees from 74 countries according to the BIO. For more information, visit http://convention.bio.org/

Contact information

Celltrion, Inc.
Gunn Lee, +82 32 850 5168
Gunhyuk.lee@celltrion.com
or
Heewon Park, +82 32 850 5356
Heewon.park@celltrion.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Groupe ADP Wins Many Overseas and International Contracts22.5.2019 14:11:00 EESTTiedote

ADP Ingénierie, company member of Groupe ADP (Paris:ADP), recently won a series of new international and French overseas contracts to provide design missions, research and technical assistance missions to major international airports. China, on the airport area encompassing Hong-Kong and Shenzhen: Mission to realize a prospecting study on traffic and airport capacity within the zone in order to help with the development of the international airport of Shenzhen. This region of southeastern China concentrates a high density of aircrafts in flight due to the proximity of several airports with significant traffic. Taiwan, for Taipei Taoyuan International Airport: Simulation study mission for the development of the air traffic. Taipei Airport welcomed 46.5 million passengers in 2018. Vietnam, for Hanoi's Noi Bai International Airport: 9-month study mission on the expansion of the airport and implementation of the master plan for 2030 and 2050. Greece, for Athens Eleftherios Venizelios Inter

OpenGate Capital Completes Acquisition of SMAC from Colas Group22.5.2019 10:00:00 EESTTiedote

OpenGate Capital, a global private equity firm, announced today that it has acquired SMAC, a global manufacturer of waterproofing and building envelope solutions, from Colas Group (EPA : RE). Financial terms were not disclosed. SMAC operates across two divisions: Travaux and Industrie. SMAC Travaux specializes in waterproofing solutions typically utilized on flat roofs structures and facades. SMAC Industrie manufactures bituminous membranes, skylights and resins. As one of the largest players in the segment, SMAC has a dedicated service and maintenance business, SMAC Assistance Service, and Essemes Services, focused on fire safety maintenance. SMAC is headquartered in Issy-les-Moulineaux and has operations across France, Morocco, and South America and is supported by 3,400 employees. Founder and CEO of OpenGate Capital, Andrew Nikou, stated: “The building and construction sector continues to present many opportunities across Europe and North America that are well suited for OpenGate. W

SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC® (NALDEMEDINE), AN OPIOID-INDUCED CONSTIPATION THERAPEUTIC AGENT IN ITALY AND POLAND22.5.2019 08:15:00 EESTTiedote

SHIONOGI B.V., the European subsidiary of SHIONOGI & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and L. MOLTENI & C. DEI F.LLI ALITTI SOCIETÀ DI ESERCIZIO S.P.A. (Headquarters: Florence, Italy; Managing Director : Giuseppe Seghi Recli, hereafter “Molteni”) announced today that Shionogi and Molteni concluded a contract for the distribution and sale of RIZMOIC® (naldemedine) for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative in the two key European markets, Italy and Poland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521005648/en/ Shionogi has built a strong heritage in research-based medicine. The company’s research and development efforts target pain/central nervous system as one of its priority areas in the mid-term business plan. The company constantly strives to improve the quality of life of patients wh

Azbil Launches an Enhanced Thermal Micro Flow Rate Liquid Flow Meter Capable of Measuring Flows of 0.5 to 50 mL/min, Adds Functionality to Existing Lineup22.5.2019 07:56:00 EESTTiedote

Azbil Corporation (TOKYO:6845) announced that it has enhanced its Thermal Micro Flow Rate Liquid Flow Meter Model F7M (hereafter, "F7M flow meter") lineup by introducing a model with an increased measurement range of up to 50 mL/min, while adding new functionality to existing models. Sales commenced in May. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521006021/en/ Thermal Micro Flow Rate Liquid Flow Meter Model F7M (Photo: Business Wire) Based on the company's years of experience bringing reliable gas flow meters to market, Azbil originally launched two models of the F7M flow meter in 2017, with one model capable of measuring micro flow rates as low as 0.1 mL/min—a level that was considered until that point to be difficult to measure. The company launched the new F7M flow meter and added functionality to the existing lineup in response to the ever diverse needs of customers and the limited availability of flow meters t

NIPPON Platform Has Established the Ninth Overseas Branch "NIPPON Platform OÜ" in Estonia22.5.2019 05:00:00 EESTTiedote

NIPPON Platform Co., Ltd. (CEO: Jun Takagi, Tokyo, Japan) established the subsidiary "NIPPON Platform OÜ" in Estonia on 8 May 2019. This is the ninth overseas branch for NIPPON Platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190521006004/en/ Overseas Subsidiaries (Graphic: Business Wire) “Making Japan into a cashless society” and “Revitalizing local societies and rural development with small and medium-sized retailers” are the motto for NIPPON Platform, and we provide various cashless payment solutions. • As a deployment base for the EU market Estonia is the most northerly of the three Baltic states, and has a population of 1.3 million people. Estonia has experienced rapid growth. Key sectors include manufacturing and IT. The parking charge may be paid via the mobile phone. 95% of residents in Estonia use the system to submit their annual income tax returns, and it will be completed in 5 minutes. Estonia is one of t

Jefferies Establishes Global Microstrategy Research22.5.2019 03:00:00 EESTTiedote

Jefferies announced today the appointment of Desh Peramunetilleke as Head of Global Microstrategy Product in Equity Research. He is based in the firm’s Hong Kong office. Desh heads up the newly-formed Microstrategy team, which includes Mahesh Kedia, Shrikant Kale, Barnis Yuen, Jeffrey Tong and Jenny Wu. Microstrategy is a bottom-up product that uses company fundamentals to create insights into markets and sectors, and combines it with top-down macro trends to develop systematic investment strategies, diagnostic screens and proprietary risk scores for clients all over the world and across investment styles. “We are very excited to have Desh join Jefferies’ leading equities platform,” commented Peter Forlenza, Jefferies’ Global Head of Equities. “We are substantially expanding our Asian equities platform given our outlook on the Asian regional markets and the opportunity. Jefferies is perhaps singular in the industry currently to have the intent and ability to enlist such impressive team

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme